President Donald Trump says he’ll sign an executive order on Monday intended to lower the cost of drugs in the U.S.

Deutsche Bank AG boosted its stake in Regeneron Pharmaceuticals by nearly 22% in Q4, now holding 539,269 shares valued at ...

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...

Cantor Fitzgerald gave Regeneron a financial pick-me-up by nudging its 2025 EPS forecast to $26.88 from $26.38. This slight ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.

The last upgrade for Regeneron Pharmaceuticals Inc happened on February 5, 2025 when Leerink Partners raised their price target to $834. Leerink Partners previously had a market perform for ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $762.00 to $834. ...

Regeneron Pharmaceuticals has announced a new manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies to enhance its production capacity for biologic medicines at Fujifilm's ...

Regeneron and Fujifilm’s manufacturing team-up comes as an onshoring production zeal grips many drugmakers operating in the U.S. The recent trend, which has been marked by major manufacturing ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to help manufacture its medicines in the US, as the threat of tariffs looms ...